Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.57 | -0.39 | -0.19 | -0.16 |
| FCF Yield | -20.12% | -14.65% | -8.93% | -6.80% |
| EV / EBITDA | -3.21 | -5.70 | -3.75 | -15.15 |
| Quality | ||||
| ROIC | -37.23% | -61.02% | -40.08% | -30.88% |
| Gross Margin | 23.12% | 4.46% | -21.66% | 8.96% |
| Cash Conversion Ratio | 0.77 | 0.88 | 0.35 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.03% | 63.71% | 126.54% | 80.13% |
| Free Cash Flow Growth | -24.15% | -148.45% | 39.07% | -280.58% |
| Safety | ||||
| Net Debt / EBITDA | 1.14 | 1.14 | 2.19 | 1.57 |
| Interest Coverage | -304.71 | -3,608.87 | -4,467.76 | -61.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 37.71 | 5.87 |
| Cash Conversion Cycle | 130.61 | -8.54 | 0.33 | 280.99 |